Inotec AMD

Cambridge, United Kingdom· Est. 2005

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Inotec AMD is a commercial-stage medical device company addressing the significant global burden of chronic wounds through its innovative NATROX® O₂ topical oxygen delivery system. The device has garnered strong clinical support, including high-level guideline recommendations from international bodies like the IWGDF and ADA for diabetic foot ulcers. With a growing evidence base, key distributor partnerships, and availability through major channels like the NHS Supply Chain, the company is positioned to capture share in the large and costly chronic wound care market.

Wound CareDiabetic Foot UlcersChronic Wounds

Technology Platform

The NATROX® O₂ system is a wearable medical device that uses electrolysis to generate pure, humidified oxygen from water, delivering continuous topical oxygen therapy (cTOT) directly to the wound bed via a specialized dressing.

Opportunities

The inclusion of Topical Oxygen Therapy in major international clinical guidelines (IWGDF, ADA) creates a significant reimbursement and adoption tailwind.

The large and growing global burden of chronic wounds, driven by diabetes and aging populations, represents a substantial addressable market for an effective adjunctive therapy.

Risk Factors

Market adoption is heavily dependent on securing consistent reimbursement from diverse payers and health systems, which can be a slow and uncertain process.

The company faces competition from other advanced wound care modalities and must continuously generate health economic data to prove cost-effectiveness.

Competitive Landscape

Inotec competes in the advanced wound care market against established modalities like negative pressure wound therapy, advanced antimicrobial dressings, and growth factors. Within the topical oxygen niche, it faces competition from other TOT devices. Its competitive edge lies in the continuous (24/7) delivery, wearable design, and strong level 1 clinical evidence supporting its use.